reason report
bottom line follow earn call remain
cautiou dplo dplo guid robust pipelin
rfp activ much like time last year
strong pipelin activ sell season posit believ
dplo need show substanti client win drive improv
investor sentiment last quarter concern
manag seem pivot strategi toward tri
win larger health system hospit client quarter
manag stress potenti larg win activ
go larg health system hospit employ client
continu believ strategi like place dplo even
greater competit larg vertic integr pbm
specialti pharmaci current pressur dplo busi
overal continu view pharmaceut suppli chain
difficult competit market mp
op continu battl volum acquir
specialti scale follow purchas mp specialti
busi optum recent acquir avella believ
intens competit continu pressur dplo busi
warrant caution maintain mp dplo maintain
pt
remain concern dplo strategi target larger
health plan hospit employ group call dplo
stress new strategi target larger hospit system
employ health plan manag report
see strong activ hospit system encourag
recent contract award advanc discuss
strong pipelin health plan concern dplo
may focus much win larg deal may place
dplo even competit larger integr pbm
specialti pharmaci though comment rfp pipelin activ
sound encourag heard commentari
believ competit deal intens
net debt total capit
year price history/av daili volume mil dplo
compani inform svb leerink llc research
revenu million ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
specialti competit remain intens dplo look
partnership countermeasur dplo continu grow
infus volum support manag prior comment
pressur face specialti one month aberr
manag explain remain concern increas
competit pressur tougher reimburs environ
sound like larger integr player continu use narrow network
aggress channel manag techniqu reimburs
pressur continu combat competit pressur sound
like dplo creat new strateg partnership
hospit health plan attempt drive volum dplo
manag character countermeasur manag
discuss role independ player catalyz forc
behind partnership sound like
partnership may help drive infus growth accord
manag health plan fragment pharma
suppli chain vendor mean may fewer competit
pressur case result sound like dplo
success establish partnership help lead infus
growth manag explain track sign
particip provid agreement
guidanc disappoint dplo revis ep
guidanc quarter disappoint view underscor
continu pressur face busi ep expect
rang behind previou guid
 behind prior svb leerink/consensu
midpoint ep guidanc revis manag
re-affirmed adj ebitda revenu guidanc manag continu
anticip brand inflat trend rang target
save new cfo davison sound
like dplo focus de-lever pay debt
oper improv togeth anticip increas infus
volum reportedli led manag guid adj ebitda ramp
encourag manag anticip continu
increas infus volum believ market remain hyper
manag expect propos rebat rule
materi impact seen littl demand po rebat model
interest hear call manag
believ propos rebat rule depart
human servic hh materi impact dplo busi
given focu propos rule medicar medicaid
manag explain pbm castiarx limit
govern busi current associ rebat
expect immateri knock-on effect
commerci market manag explain believ could
simpli shift profit lever make lost rebat dollar keep
pbm whole believ dplo like could employ lever
remain concern heighten rebat scrutini pose threat
dplo manag also highlight current offer model
provid pos po rebat seen littl
demand see much uptick
model updat follow result revis guidanc
updat model revenu estim increas
slightli reflect revenu beat quarter chang ep
estim pt unchang
diplomat pharmaci inc diplomat oper fourth largest specialti pharmaci sp
 largest independ specialti pharmaci script believ specialti
pharmaci industri continu benefit sever key trend includ price inflat
new specialti drug launch expand indic exist drug potenti
acceler biosimilar specialti drug age popul competit strength
diplomat provid client addit believ diplomat uniqu posit
capit limit distribut specialti agreement substanti runway grow
market share specialti drug administ pharmaci medic benefit
also expect diplomat focu opportun within infus market
benefit ebitda margin expans new exist therapeut categori
specialti busi grow dplo face heighten competit larger retail
chain specialti pharmaci cvs/aet ci/esrx deal believ plan
get aggress steer volum specialti pharmaci also
believ larger pbm get aggress prefer part network
also concern highli competit pbm market appar lack advantag
castiarx bring middl market custom given concern well manag
lack visibl busi growth driver rate share diplomat dplo market
diplomat share trade ebitda higher group averag
believ dplo deserv trade
discount peer group given dplo lack growth loss pbm divis inconsist
commun highli competit market environ next month expect
dplo trade ebitda given increasingli competit market
driven mega-merg unfavor mix shift lower margin product loss pbm
busi lower script volum rate share dplo market perform
competit high specialti pharmaci industri highli competit current
domin three player esrx given rapid specialti market growth
spur new drug approv drug price inflat expect specialti market remain
attract new entrant market particip diplomat also sever retail partnership
pbm relationship custom develop acquir specialti pharmaci
may result custom loss diplomat
reimburs pressur could impact growth profit specialti drug spend
scrutin payor includ govern payor medicar medicaid legisl
bodi pressur mount limit reimburs runaway cost specialti drug
could put downward pressur price trend could advers impact diplomat growth
requir diplomat deliv addit valu ad servic payor
limit distribut agreement drug access emerg limit distribut
model specialti drug manufactur repres opportun diplomat also risk
compani longer abl secur limit distribut agreement lose access drug
specif manufactur diplomat current reli celg mp signific portion
drug
 integr rapid expans diplomat incorpor tuck-in acquisit
complement organ growth risk associ integr custom
technolog servic distribut diplomat excess facil capac posit
compani absorb volum increas success growth also reli hire new
employe given high-touch servic compon associ specialti pharmaci well
retain key employe manag member
litig risk diplomat handl sensit patient inform reli inform
technolog system could becom compromis secur breach could
result lawsuit exposur compani also provid limit compound servic could
expos compani certain litig risk
sale busi dplo could sell larg manag care plan retail chain
incom statement model fiscal year end decemb mm
sale
sale
sale
sale
impair intang asset
chang fair valu redeem common
termin exist stock redempt
less net incom loss attrib nci
net incom attrib diplomat
alloc pref sharehold
gaap net incom alloc common
incom statement model fiscal year end decemb mm
chang fair valu redeem common
termin exist stock redempt
equiti loss non-consol entiti
